The Motley Fool
12 Jul 2026, 00:15 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
AbbVie has agreed to acquire Apogee Therapeutics for $10.9 billion. — A multi-billion dollar acquisition expands the company's pipeline and provides new growth avenues to offset patent losses.
+0.60The acquisition brings in zumilokibart, a late-stage drug for atopic dermatitis, and a pipeline of respiratory drugs. — Adding late-stage candidates in core therapeutic areas reduces R&D risk and accelerates the path to new revenue streams.
+0.40Skyrizi and Rinvoq are successfully offsetting the revenue decline from Humira's 2023 patent expiration. — Positive evidence of a successful transition between flagship products supports the company's long-term valuation and dividend stability.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is praised for its strategic acquisition of Apogee Therapeutics, its ability to maintain dividend growth, and a strong drug pipeline.
The company is being acquired by AbbVie for $10.9 billion due to its attractive drug candidates.
Mentioned only as the parent company from which AbbVie was spun off, with no current sentiment expressed.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
8h ago
